[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357538-105":59,"doc-detail-357538-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","metformin-sensitizes-hrher2-breast-cancer-cells-to-cdk46-inhibitor-via-suppressing-of-pi3kaktmtor-signaling-pathway-research-article","Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway - Research Article","","CDK4/6 inhibitors are recommended as first-line therapy for HR+/HER2- breast cancer, yet their efficacy is limited by toxicity and resistance. This study evaluates whether metformin can sensitize HR+/HER2- breast cancer to palbociclib and clarifies the mechanism. Using in vitro HR+/HER2- cell lines and in vivo transplanted tumor mouse models, metformin plus palbociclib synergistically suppresses proliferation and migration, promotes apoptosis, and inhibits PI3K/AKT/mTOR signaling. Metformin downregulates CDK4 and enhances palbociclib suppression of Cyclin D1/E2F and Rb phosphorylation. Combination therapy also suppresses tumor growth in vivo.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/metformin-sensitizes-hrher2-breast-cancer-cells-to-cdk46-inhibitor-via-suppressing-of-pi3kaktmtor-signaling-pathway-research-article/357538/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/metformin-sensitizes-hrher2-breast-cancer-cells-to-cdk46-inhibitor-via-suppressing-of-pi3kaktmtor-signaling-pathway-research-article/357538.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why was this study designed to test metformin with CDK4/6 inhibitors in HR+/HER2- breast cancer?","Question",{"text":113,"@type":114},"CDK4/6 inhibitors are recommended first-line for HR+/HER2- breast cancer, but efficacy is limited and resistance develops. Metformin has known antitumor potential and may enhance cancer therapy outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What experimental approaches were used to evaluate the combination of metformin and palbociclib?",{"text":118,"@type":114},"The study used human HR+/HER2- breast cancer cell lines in vitro and transplanted tumor mouse models in vivo to test combined anti-tumor effects and underlying mechanisms.",{"name":120,"@type":111,"acceptedAnswer":121},"How does metformin enhance the effect of palbociclib at the molecular level?",{"text":122,"@type":114},"The combination suppresses the PI3K/AKT/mTOR pathway, downregulates CDK4 protein expression, and leads to deeper inhibition of Cyclin D and E2F, with enhanced inhibition of Rb phosphorylation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},357538,1790185775,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Drug Design, Development and Therapy  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nMetformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway  \nLin Zhu 1 , Jiawen Yang 1 , Fengmei Li2 , Dandan Wang 1 , Wenda Zhang 1 , Jingmin Zhang 1 , Zhenfeng Duan 3 , Youhong Hu 1 , Yubing Zhou 1  \n1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 2Department of Obstetrics and Gynecology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 3Department of Orthopedic Surgery, Sarcoma Biology Laboratory, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA  \nCorrespondence: Yubing Zhou; Youhong Hu, Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People’s Republic of China, Email [fcczhouyb@zzu.edu.cn](fcczhouyb@zzu.edu.cn); [hyouhong@163.com](hyouhong@163.com)  \n\n| Purpose: CDK4/6 (Cyclin-dependent kinase 4/6) inhibitors are recommended as the first-line treatment for Hormone receptorpositive/human epidermal growth receptor 2-negative (HR+/HER2-) breast cancer, but their efficacy is limited. Metformin, a widely used antidiabetic drug, has demonstrated antitumor potential and can enhance the efficacy of various cancer therapies. Nevertheless, its specific role in sensitizing HR+/HER2-breast cancer to CDK4/6 inhibition and the underlying mechanisms remain poorly defined. Methods: In this study, the combined anti-HR+/HER2-breast cancer effects of metformin with CDK4/6 inhibitor palbociclib and its potential mechanisms were investigated using human HR+/HER2-breast cancer cell lines in vitro and transplanted tumor mouse models in vivo. Results: Our study demonstrated that the combination of metformin and palbociclib synergistically inhibited proliferation and migration, and promoted apoptosis in HR+/HER2-breast cancer cells. This synergistic anticancer effect was linked to suppression of the PI3K/AKT/mTOR pathway. Mechanistically, metformin downregulated CDK4 protein expression, and its combination with palbociclib led to a more profound suppression of Cyclin D1 and E2F, along with enhanced inhibition of Rb phosphorylation. Moreover, the metformin-palbociclib combination synergistically suppressed tumor growth in vivo.\u003Cbr>Conclusion: Our findings highlighted that metformin could serve as an adjunctive therapy alongside CDK4/6 inhibitors, offering a promising synergistic treatment strategy for HR+/HER2-breast cancer.\u003Cbr>Keywords: metformin, CDK4/6 inhibitor, palbociclib, HR+/HER2-breast cancer, PI3K/AKT/mTOR pathway |\n| --- |\n| Introduction\u003Cbr>HR+/HER2- breast cancer is the most prevalent type of breast cancer.1 Investigations have shown that a significant proportion of patients with HR+/HER2-breast cancer present at advanced stages.2 In 2015, the approval of CDK4/6 inhibitors added an additional option for the systemic treatment of patients with advanced breast cancer.3 Currently, the US Food and Drug Administration (FDA) has approved three selective CDK4/6 inhibitors, including palbociclib, ribociclib, and abemaciclib, for the treatment of HR+/HER2-metastatic breast cancer.4 However, with several years of clinical experience, CDK4/6 inhibitors have increasingly revealed certain limitations. The use of CDK4/6 inhibitors leads to a high frequency and incidence of myelosuppression, leukopenia and neutropenia.5 Additionally, resistance to CDK4/6 inhibitors is a growing concern, probably due to mutation-activated epigenetic changes in the tumor cells.6 Over time, side effects and resistance to CDK4/6 inhibitors have progressively diminished their clinical efficacy. Therefore, it is of great significance to search for some new effective and low-toxic treatments or drugs to enhance the efficacy of CDK4/6 inhibitors and treat HR+/HER2-breast cancer. |\n","cbCaiblnlIIIBppQ","https://ap.wps.com/l/cbCaiblnlIIIBppQ","pdf",17537031,18,"English","# Introduction\n# Purpose\n# Methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"Why was this study designed to test metformin with CDK4/6 inhibitors in HR+/HER2- breast cancer?\",\"answer\":\"CDK4/6 inhibitors are recommended first-line for HR+/HER2- breast cancer, but efficacy is limited and resistance develops. Metformin has known antitumor potential and may enhance cancer therapy outcomes.\"},{\"question\":\"What experimental approaches were used to evaluate the combination of metformin and palbociclib?\",\"answer\":\"The study used human HR+/HER2- breast cancer cell lines in vitro and transplanted tumor mouse models in vivo to test combined anti-tumor effects and underlying mechanisms.\"},{\"question\":\"How does metformin enhance the effect of palbociclib at the molecular level?\",\"answer\":\"The combination suppresses the PI3K/AKT/mTOR pathway, downregulates CDK4 protein expression, and leads to deeper inhibition of Cyclin D and E2F, with enhanced inhibition of Rb phosphorylation.\"}]","Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway - Research Article | PDF",1790130300,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd536cfb768c44af3aee16078a92690b.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c1d535c3b0b1ed22b5e4380f7c51a21.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/982adcf57f21d82640d66e7713928fee.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42e2168f6a354a0f77f9c94e13b22967.webp",980,1268]